Research
Energy balance
Participants treated with SAR425899 lost more weight, fat mass, and fat free mass compared to those on placebo (p < 0.05).
SAR425899 may enhance weight loss and body composition improvements.
StrongSupportsmedium confidence
Those treated with SAR425899 lost more weight, fat mass, and fat free mass (p < 0.05).
Why this rating
Based on the randomized controlled trial design.
Source
<scp>Glucagon‐like peptide</scp>‐1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial
Karen D. Corbin et al. · Obesity · 2023
rct · n=35Cited 26×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →